what we do?

Rooted in science

sourced worldwide

LianBio is a biotechnology company focused on bringing paradigm-shifting medicines to patients.


Scroll to see more



Our Mission

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.

Learn More


Our Future

We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.

Stay up to date

News & Events

November 19, 2020

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China


November 3, 2020

LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China


October 29, 2020

LianBio Announces $310 Million Crossover Financing


August 11, 2020

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

See All

We are here for you

Contact Us

Email us directly:

IR@LianBio.com careers@lianbio.com

Office Addresses

Shanghai Office
9th Floor, Kerry Parkside, 1155 Fangdian Road
Unit 901-902
Shanghai, PRC 201204

New Jersey Office
103 Carnegie Center Drive
Suite 215
Princeton, NJ 08540